Abstract
ABSTRACTMemantine's efficacy has been demonstrated in patients with moderate to severe Alzheimer's disease. However, memantine therapy is not typically used in treating Parkinson's disease dementia (PDD), although the deviating glutamatergic pattern evidenced in neuropathological findings suggests that N‐methyl D‐aspartate receptor antagonists in patients with Lewy‐body disorder may be effective. Therefore, we conducted this longitudinal study to confirm the efficacy of memantine for PDD by analyzing comparative changes in regional cerebral blood flow (rCBF) and neuropsychological tests before and after memantine administration in PDD. A total of 18 patients with PDD were enrolled in this study. All patients underwent technetium‐99m hexamethylpropyleneamine oxime single photon emission computed tomography and completed neuropsychological tests before and 12 months after memantine administration. This study showed that there was no significant difference in cognitive functioning before and after memantine administration. No significant difference in rCBF was observed in any regions at baseline compared to 12 months after memantine administration. Our results suggest that memantine delays the speed of deterioration in cognitive functioning and behavioral symptoms in PDD because we found no significant changes in rCBF and cognition after memantine treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Imaging Systems and Technology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
